1. Home
  2. CASI vs PIII Comparison

CASI vs PIII Comparison

Compare CASI & PIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CASI
  • PIII
  • Stock Information
  • Founded
  • CASI 1991
  • PIII 2015
  • Country
  • CASI China
  • PIII United States
  • Employees
  • CASI N/A
  • PIII N/A
  • Industry
  • CASI Biotechnology: Pharmaceutical Preparations
  • PIII Medical/Nursing Services
  • Sector
  • CASI Health Care
  • PIII Health Care
  • Exchange
  • CASI Nasdaq
  • PIII Nasdaq
  • Market Cap
  • CASI 35.0M
  • PIII 30.8M
  • IPO Year
  • CASI 1996
  • PIII N/A
  • Fundamental
  • Price
  • CASI $2.21
  • PIII $0.18
  • Analyst Decision
  • CASI Strong Buy
  • PIII Buy
  • Analyst Count
  • CASI 1
  • PIII 3
  • Target Price
  • CASI $6.00
  • PIII $2.38
  • AVG Volume (30 Days)
  • CASI 8.1K
  • PIII 1.1M
  • Earning Date
  • CASI 03-27-2025
  • PIII 03-27-2025
  • Dividend Yield
  • CASI N/A
  • PIII N/A
  • EPS Growth
  • CASI N/A
  • PIII N/A
  • EPS
  • CASI N/A
  • PIII N/A
  • Revenue
  • CASI $22,055,000.00
  • PIII $1,476,630,000.00
  • Revenue This Year
  • CASI N/A
  • PIII $21.45
  • Revenue Next Year
  • CASI $134.79
  • PIII N/A
  • P/E Ratio
  • CASI N/A
  • PIII N/A
  • Revenue Growth
  • CASI N/A
  • PIII 25.38
  • 52 Week Low
  • CASI $2.04
  • PIII $0.17
  • 52 Week High
  • CASI $7.67
  • PIII $1.12
  • Technical
  • Relative Strength Index (RSI)
  • CASI 35.91
  • PIII 39.88
  • Support Level
  • CASI $2.15
  • PIII $0.18
  • Resistance Level
  • CASI $2.49
  • PIII $0.19
  • Average True Range (ATR)
  • CASI 0.15
  • PIII 0.01
  • MACD
  • CASI 0.00
  • PIII -0.00
  • Stochastic Oscillator
  • CASI 35.42
  • PIII 25.66

About CASI CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

About PIII P3 Health Partners Inc.

P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.

Share on Social Networks: